AR is different. So is our valve.
A transcatheter solution for aortic regurgitation has been impossible—until now.

Other TAVI valves rely on calcification in and around the annulus for anchoring and stability. In patients with aortic regurgitation, there is often no calcification for the TAVI to hold onto, leaving patients with aortic regurgitation no treatment options other than surgery.

AR patients are at risk

Untreated severe, symptomatic AR patients have a 1 year mortality rate of 24%.

Severe AR is undertreated

74% of severe, symptomatic AR patients do not receive treatment within a year of diagnosis.
The Trilogy Valve with locator technology finally gives high-risk patients with severe, symptomatic aortic regurgitation a TAVI treatment option. Trilogy’s locators attach to the native leaflets for secure anchoring even in the absence of calcium, while ensuring commissural alignment.

Alignment
Locator technology ensures proper alignment with native anatomy before the valve is deployed.

Anchoring
Locators anchor the valve by attaching to native leaflets for secure placement and sealing.

Deployment
Commissure-to-commissure alignment upon deployment achieved.
The Trilogy Valve

The only TAVI system approved for aortic regurgitation.

- Large, open cell design enables future coronary access
- Porcine pericardial tissue
- Supra-annular, self-expanding nitinol frame
- Sealing ring provides sufficient anchoring and annular conformability
- Locator technology allows alignment with native anatomy

Locator Alignment
Valve Deployment
AR Treated
The Trilogy Delivery System
Engineered from the ground up for precision and reliability from access to deployment.

Single action deployment through a simple advancement mechanism

Integrated rotation allows for simple and straightforward commissural alignment

Catheter deflection allows the centering of the valve above the annulus

The Trilogy Introducer Sheath
85 cm pre-shaped sheath protects valve and patient anatomy into ascending aorta, up until valve alignment and positioning.

Indications: The JenaValve Trilogy Heart Valve System is indicated for use in patients with native symptomatic, severe aortic regurgitation (AR) or symptomatic, severe aortic stenosis (AS), who are judged by a Heart Team (including a cardiac surgeon), to be at high or greater risk for surgical aortic valve replacement (AVR), with an STS score ≥ 8% at 30 days, or other comorbidities (e.g., porcelain aorta, frailty, chest wall irradiation) that are not captured by the STS risk calculator.

Contraindications: The JenaValve Trilogy Heart Valve System is contraindicated for use in patients who have known hypersensitivity or contraindication to Nitinol (titanium and/or nickel), an anti-coagulation/anti-platelet regimen or contrast medium that cannot be managed with premedication, or who have active bacterial endocarditis or other active infections.

US: CAUTION – Investigational Device. Limited by Federal (or United States) law to investigational use.